Auf dieser Seite
BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 5, 2026 10-K/10-Q Aug 5, 2026
$8,10
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$6,0052-Wochen-Tief
$11,2252-Wochen-Hoch
Marktkapitalisierung (MRQ)
$2.07B
P/E (TTM)
-5.4
EPS (TTM)
$-1.49
Umsatz (TTM)
$941M
Ihre Abzeichen
52W-Spanne
$6–$11
Analystenbewertung
BUY
Kursziel
$21
P/E
-5.4
ROE
87.8%
Nettogewinnmarge
-40.9%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
BCRX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$8.10
Marktkapitalisierung (MRQ)
$2.07B
P/E (TTM)
-5.4
EPS (TTM)
$-1.49
Umsatz (TTM)
$941M
ROE (TTM)
87.8%
Verschuldungsgrad (MRQ)
-0.9
52W-Spanne
$6–$11
BCRX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über BioCryst Pharmaceuticals, Inc. - Common Stock Unternehmensübersicht von Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter435
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
Freier Cashflow$345M2016-12-31 → 2025-12-31
Nettogewinnmarge-40.9%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | BCRX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -5.45-Jahres-Durchschnitt ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.25-Jahres-Durchschnitt ≈6.7 | ≈6.7 | 22.5 | Unterbewertet | |
| K/B (MRQ) | -4.65-Jahres-Durchschnitt ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.25-Jahres-Durchschnitt ≈-281.5 | ≈-281.5 | · | · | |
| Kurs / FCF (TTM) | 5.55-Jahres-Durchschnitt ≈-13.6 | ≈-13.6 | · | · | |
| Kurs / Cashflow (TTM) | 5.55-Jahres-Durchschnitt ≈-13.9 | ≈-13.9 | · | · | |
| EV / Umsatz (TTM) | 2.25-Jahres-Durchschnitt ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.75-Jahres-Durchschnitt ≈-14.4 | ≈-14.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | BCRX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -33.3%5-Jahres-Durchschnitt ≈-32.2% | ≈-32.2% | -247.1% | Spitzenklasse | |
| EBITDA Margin (EBITDA-Marge) | 39.1%5-Jahres-Durchschnitt ≈-31.8% | ≈-31.8% | -247.1% | Spitzenklasse | |
| Vorgewinnmarge (TTM) | -40.5%5-Jahres-Durchschnitt ≈-52.6% | ≈-52.6% | -765.9% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -40.9%5-Jahres-Durchschnitt ≈-53.3% | ≈-53.3% | -225.1% | Spitzenklasse | |
| ROA (TTM) | -75.8%5-Jahres-Durchschnitt ≈-18.2% | ≈-18.2% | -39.4% | Spitzenklasse | |
| ROE (TTM) | 87.8%5-Jahres-Durchschnitt ≈42.1% | ≈42.1% | -59.7% | Schwach | |
| ROIC | -282.4%5-Jahres-Durchschnitt ≈-118.5% | ≈-118.5% | -63.3% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | BCRX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | -0.95-Jahres-Durchschnitt ≈-0.7 | ≈-0.7 | 0.2 | Geringe Verschuldung | |
| Liquiditätsgrad (MRQ) | 2.35-Jahres-Durchschnitt ≈3.7 | ≈3.7 | 10.1 | Geringe Liquidität | |
| Quick Ratio (MRQ) | 2.25-Jahres-Durchschnitt ≈2.5 | ≈2.5 | 5.8 | Geringe Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | -0.95-Jahres-Durchschnitt ≈-0.7 | ≈-0.7 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | BCRX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 94.1%5-Jahres-Durchschnitt ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 47.8%5-Jahres-Durchschnitt ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 117.9% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | BCRX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 1.75-Jahres-Durchschnitt ≈0.8 | ≈0.8 | 0.0 | Spitzenklasse | |
| Inventory Turnover (Lagerumschlag) | 2.85-Jahres-Durchschnitt ≈0.9 | ≈0.9 | 2.0 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 9.45-Jahres-Durchschnitt ≈7.4 | ≈7.4 | 4.9 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$2.0M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
23.2%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31. März 2026 | $-0.09 | $0.05 | -281.8% | |
| 31. Dezember 2025 | $0.01 | $0.04 | -74.1% | |
| 30. September 2025 | $0.06 | $0.04 | 67.1% | |
| 30. Juni 2025 | $0.04 | $0.01 | 179.7% | |
| 31. März 2025 | $0.00 | $-0.07 | 100.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $875M | $451M | $331M | $271M | $157M |
| Betriebsgewinnmarge % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Nettoergebnis | $264M | $-89M | $-227M | $-247M | $-184M |
| Verwässerte EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Liquiditätsgrad | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $345M | $-53M | $-97M | $-163M | $-145M |
Institutionelle Eigentümer (13F) 345 Einreicher · $2.8B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
345
Gehaltener Wert
$2.8B
Neue Positionen
55
Geschlossene Positionen
34
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 55 (-22 vs. Vorquartal) | 34 (-5 vs. Vorquartal) | 137 (+20 vs. Vorquartal) | 87 (+8 vs. Vorquartal) | +4.1M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $238.930.360 | 23.893.036 | 8,46% | Aktien |
| VANGUARD GROUP INC | $173.732.325 | 22.273.375 | 6,15% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 5,61% | Aktien |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 5,38% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 5,35% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 4,03% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 3,95% | Aktien |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 3,90% | Aktien |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 3,65% | Aktien |
| JANUS HENDERSON GROUP PLC | $84.853.520 | 8.908.506 | 3,01% | Aktien |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 2,94% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 2,40% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $62.493.232 | 6.248.046 | 2,21% | Aktien |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 1,88% | Aktien |
| UBS Group AG | $50.782.800 | 5.078.280 | 1,80% | Aktien |
| BANK OF AMERICA CORP /DE/ | $48.012.840 | 4.801.284 | 1,70% | Aktien |
| GOLDMAN SACHS GROUP INC | $44.818.738 | 4.481.874 | 1,59% | Aktien |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,42% | Aktien |
| Nuveen, LLC | $40.072.370 | 4.007.237 | 1,42% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,20% | Aktien |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,13% | Aktien |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,02% | Aktien |
| JANE STREET GROUP, LLC | $27.626.830 | 2.762.683 | 0,98% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $27.187.810 | 2.718.781 | 0,96% | Aktien |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 0,92% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 0,90% | Aktien |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 0,89% | Aktien |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 0,89% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 0,83% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 0,83% | Aktien |
| NORTHERN TRUST CORP | $22.557.310 | 2.255.731 | 0,80% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $22.143.020 | 2.214.302 | 0,78% | Aktien |
| MORGAN STANLEY | $19.996.852 | 1.999.684 | 0,71% | Aktien |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,67% | Aktien |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,66% | Aktien |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,66% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,65% | Aktien |
| STIFEL FINANCIAL CORP | $18.262.340 | 1.826.234 | 0,65% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,62% | Aktien |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,62% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $16.428.740 | 1.642.874 | 0,58% | Aktien |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,58% | Aktien |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,58% | Aktien |
| Legal & General Group Plc | $14.555.141 | 1.455.514 | 0,52% | Aktien |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,48% | Aktien |
| Invesco Ltd. | $12.337.830 | 1.233.783 | 0,44% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,42% | Aktien |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,42% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,42% | Aktien |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,40% | Aktien |
Aktivisten & 5%+-Eigentümer 15 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 Einreichungen | 31. Juli 2018 | · | Erste Einreichung | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2. April 2018 | · | Erste Einreichung | Passive Anlage | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 Einreichungen | 16. August 2016 | · | Erste Einreichung | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 Einreichungen | 23. Oktober 2012 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Julian C. Baker, Felix J. Baker ×4 Einreichungen | 13. Oktober 2011 | · | Erste Einreichung | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 Einreichungen | 20. August 2007 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 7. Dezember 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 7. Dezember 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 7. Dezember 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 13. Oktober 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 26. Februar 2004 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 25. Februar 2004 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 24. Februar 2004 | · | Erste Einreichung | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 Einreichungen | 31. Oktober 2003 | · | Erste Einreichung | · | SEC |
| William W. Featheringill | 14. Februar 2002 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 51 Insider · 21 Führungskräfte · 30 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17. Dezember 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19. Dezember 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21. Februar 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16. März 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22. Dezember 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14. März 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13. Mai 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 6. April 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31. März 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19. Dezember 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14. November 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10. März 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15. Dezember 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28. Januar 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15. März 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7. Februar 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12. März 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31. Juli 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31. Juli 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31. Juli 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16. Mai 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Direktor | 31. August 2026 A | 47.821 | 0 | 1 | $-100.285 |
| Jill C. Milne | Direktor | 31. August 2026 A | 33.226 | 0 | 0 | $0 |
| Steven Frank | Direktor | 31. August 2026 A | 36.747 | 0 | 0 | $0 |
| Jon P Stonehouse | Direktor | 31. August 2026 A | 1.340.419 | 0 | 0 | $0 |
| Vincent Milano | Direktor | 31. August 2026 A | 109.642 | 0 | 0 | $0 |
| Theresa Heggie | Direktor | 11. Juni 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Direktor | 11. Juni 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Steven K Galson | Direktor | 11. Juni 2026 A | 27.794 | 0 | 0 | $0 |
| Alan G Levin | Direktor | 11. Juni 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Direktor | 12. Juni 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Direktor | 12. Juni 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Direktor | 12. Juni 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Direktor | 13. Juni 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direktor | 28. Februar 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Direktor | 28. November 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Direktor | 20. Juni 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Direktor | 24. Mai 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | Direktor | 29. Februar 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Direktor | 2. Mai 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Direktor | 23. Mai 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Direktor | 23. Mai 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Direktor | 12. Mai 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Direktor | 13. Mai 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Direktor | 13. Mai 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Direktor | 16. Mai 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Direktor | 16. Mai 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Direktor | 18. März 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Direktor | 17. Mai 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Direktor | 4. November 2003 M | 46.785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21. Mai 2008 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 41 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,34% | 1.193.733 SH | 2. Oktober 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,42% | 155.993 NS | 31. Juli 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0,99% | 510 NS | 31. Juli 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,92% | 1.078.429 NS | 31. Juli 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 248.560 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,59% | 324.702 NS | 31. Juli 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,36% | 516.595 NS | 31. Juli 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,22% | 73.039 SH | 2. Oktober 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,17% | 4.436 NS | 31. Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 19. August 2026 | Täglich |
| ESSC · Strategy Shares | 0,14% | 5.593 NS | 31. Juli 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,14% | 18.119 SH | 2. Oktober 2026 | Täglich |
| IBB · iShares Trust | 0,13% | 1.651.139 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,13% | 2.178.966 SH | 11. September 2026 | Täglich |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 174.467 NS | 31. Juli 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 64.429 NS | 31. Juli 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 46.799 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,07% | 111.471 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 75.067 SH | 11. September 2026 | Täglich |
| IWM · iShares Trust | 0,06% | 5.937.121 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 202.979 SH | 2. Oktober 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,05% | 770.732 NS | 31. Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 19. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 99.007 NS | 31. Juli 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,01% | 11.812 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 72.998 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 336.323 SH | 11. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 52.194 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.571 NS | 31. Juli 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 286 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 19. August 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 196.622 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 19.676 SH | 19. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,00% | 51.624 SH | 19. August 2026 | Täglich |
| ISCB · iShares Trust | · | 10.494 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 766.086 SH | 11. September 2026 | Täglich |
BCRX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 17 Analysten
KAUF
Median-Ziel
$17.00
+109,9%
5 29,4%
Starker Kauf
10 58,8%
Kauf
2 11,8%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
11 Analysten · 2026-10-05Mittelwert-Ziel $20.73 +155,9%
← Unter allen Zielen
Aktueller Preis $8.10
Tief$11.00
Mittelwert$20.73
Hoch$32.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
RBC Capital erhöht PT für BioCryst Pharmaceuticals (BCRX) als Teil der Q1 2026 Ergebniserwartung in Biotech
Yahoo Finance · 5 Monate vor
BioCryst (BCRX) Rallyt um 7,10 % aufgrund von Übernahmegerüchten
Yahoo Finance · 6 Monate, 2 Wochen vor
BioCryst Pharmaceuticals, Inc. (BCRX) Eine gute Aktie zum Kauf jetzt?
Yahoo Finance · 6 Monate, 2 Wochen vor
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 5, 2026